Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR3 | P25089 | 6/20 | 0.55 |
| ▸ | FPR2 | P25090 | 6/20 | 0.55 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22644748 | 0.86 | MALT1 (0.51) | FPR3FPR2MALT1BCHEDDB1 | |
| SCHEMBL16935831 | 0.85 | MALT1 (0.50) | FPR3FPR2MALT1BCHEDDB1 | |
| SCHEMBL3201557 | 0.85 | MALT1 (0.50) | FPR3FPR2MALT1BCHEDDB1 | |
| SCHEMBL7203913 | 0.84 | MALT1 (0.59) | MALT1BCHEDDB1CRBNCA1 | |
| SCHEMBL22419858 | 0.84 | MALT1 (0.49) | MALT1BCHEDDB1CRBNCA1 | |
| SCHEMBL16011811 | 0.83 | MALT1 (0.49) | FPR3FPR2MALT1BCHEDDB1 | |
| SCHEMBL31300043 | 0.83 | CYP1A2 (0.58) | FPR3FPR2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23099401 | 0.82 | MALT1 (0.48) | MALT1BCHEDDB1CRBNCA1 | |
| SCHEMBL21659730 | 0.82 | POLB (0.56) | MALT1BCHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23181846 | 0.82 | MALT1 (0.48) | FPR3FPR2MALT1BCHEDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4522154-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220425-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2021078022-A1 | SMALL MOLECULE COMPOUND | 嘉兴特科罗生物科技有限公司 | 2021-04-29 | — | — | WO | disclosed |
| EP-3736266-A1 | COMPOUND SIMULTANEOUSLY INHIBITING LSD1 AND HDAC TARGETS AND APPLICATION THEREOF | Peking University Shenzhen Graduate School (CN) | 2020-11-11 | — | — | EP | disclosed |
| WO-2020200291-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2020-10-08 | — | — | WO | disclosed |
| EP-3689868-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas Operations, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2018102725-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20140308317-A1 | Polymeric Compounds And Methods Of Making And Using The Same | CELLCEUTIX CORPORATION (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2014093225-A2 | POLYCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CELLCEUTIX CORPORATION (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | UNIVERSITY OF WASHINGTON (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2006102159-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA AND CANCER | YALE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312287-A1 | Compound and Methods For the Treatment of Cancer and Malaria | AKR1C3, NR1H3, HCCS | FPR3 145/4885FPR2 276/4885MALT1 1039/4885 |
| US-20260092057-A1 | BCL-XL/BCL-2 DEGRADERS AND USES THEREOF | BCL2L2, BCL2A1, BCL2L1 | FPR3 3233/4885FPR2 1757/4885MALT1 51/4885 |
| US-20140308317-A1 | Polymeric Compounds And Methods Of Making And Using The Same | ALG1, CD44, MUC1 | FPR3 447/4885FPR2 815/4885MALT1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.